je.st
news
FDA Accepts Mercks NDA for Fixed-Dose Combination of Raltegravir with Lamivudine
2014-06-24 14:30:35| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. If Approved, Fixed-Dose Combination Would Be Used with Other Antiretroviral Agents for the Treatment of HIV-1 in Adults, Adolescents and Certain Pediatric Patients Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for a fixed-dose combination (FDC) of raltegravir with lamivudine for the treatment of HIV-1 infection (MK-0518B) has been accepted for standard review by the U.S. Food and Drug Administration (FDA). Language: English read more
Tags: with
combination
accepts
fda
Category:Biotechnology and Pharmaceuticals